StrokeLAST-longNCT03859063
Long-term Follow-up After Stroke (The LAST-long Trial)
A study testing Intervention in people with Stroke, run by Norwegian University of Science and Technology at 4 sites in Norway.
Trial summary
Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke
- What is being tested?
- Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 301 participants
- Where
- 4 sitesNorway
- Study dates
- 11 Apr 2019to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of first ever or recurrent stroke (ischemic stroke or hemorrhage)
- mRS < 5
- Living in Trondheim, Skedsmo or Lørenskog municipality
- Less than 10 points on Short Physical Performance Battery (SPPB) OR less than 26 points on Montreal Cognitive Assessment (MoCA) OR more than 27 points on the 7 item version of the Fatigue Severity Scale (FSS-7) OR more than 7 points on the depression or anxiety items on Hospital Anxiety and Depression Scale (HADS) OR reduced hand function (i.e. fails on Motor Assessment Scale - Advanced arm- and hand function, item 3)
- Able to understand Norwegian
- Able and willing to sign informed consent.
Who cannot join
- Life expectancy < 12 months
- Other serious diseases, judged by the medical doctor to make it difficult to comply with the intervention (i.e. serious neurological diseases or drug abuse).
Trial locations and contacts
4 sites in 1 country.
Norway4 sites
Ålesund Hospital
Ålesund, 6017
Akershus University Hospital
Lørenskog
Vestre Viken Bærum Hospital
Sandvika
St Olavs Hospital Stroke Unit
Trondheim
About this study
Official title: A Multimodal Individualized Intervention to Prevent Functional Decline After Stroke. A Randomized Controlled Trial on Long-term Follow-up After Stroke (The LAST-long Trial)
Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. These are also regarded as barriers to achieve optimal adherence to the guidelines regarding secondary prevention. The primary aim of this project is to evaluate the effectiveness of a multimodal individualized intervention to prevent functional decline in the long term after stroke.
Read the detailed description
In a clinical randomized controlled trial, participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months.
The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
Those randomized to the control group will receive standard care.
Patients living in the municipalities of Trondheim, Lørenskog and Skedsmo admitted to Akershus University Hospital or St. Olavs University Hospital will be included at the outpatients clinic 3 months after the stroke.
All patients will be re-assessed at 6, 12 and 18 months after inclusion. Primary outcome will be modified Rankin Scale at 18 months.
- Conditions
- Stroke
- Being tested
- Intervention, Control
- Keywords
- Rehabilitation, Cognition, Physical Fitness, Case Managers, Secondary prevention
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterventionBehavioural
Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
ControlBehavioural
Also called Usual care
Community based follow-up as usual
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Regular follow up by a community based stroke coordinator Receives: Behavioral: Intervention |
| Control | Active comparator | Usual care Receives: Behavioral: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Rankin Scale (mRS)
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Measured: 18 months
Secondary outcomes (76)
Modified Rankin Scale (mRS)
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Measured: 6 months
Modified Rankin Scale (mRS)
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
Measured: 12 months
Barthel Index
ADL function
Measured: 6 months
Barthel Index
ADL function
Measured: 12 months
Barthel Index
ADL function
Measured: 18 months
Nottingham IADL
Extended activities of daily life (ADL) function
Measured: 6 months
Nottingham IADL
Extended activities of daily life (ADL) function
Measured: 12 months
Nottingham IADL
Extended activities of daily life (ADL) function
Measured: 18 months
Stroke Impact Scale (SIS)
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Measured: 6 months
Stroke Impact Scale (SIS)
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Measured: 12 months
Stroke Impact Scale (SIS)
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains. The scale within each domain range from 0 to 100 and higher score denotes better health.
Measured: 18 months
The 5-level EQ-5D version (EQ-5D-5L)
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
Measured: 6 months
The 5-level EQ-5D version (EQ-5D-5L)
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
Measured: 12 months
The 5-level EQ-5D version (EQ-5D-5L)
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
Measured: 18 months
Short Physical Performance Battery (SPPB)
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Measured: 6 months
Short Physical Performance Battery (SPPB)
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Measured: 12 months
Short Physical Performance Battery
SPPB is a composite scale measuring gait and balance. The scale ranges from 0 to 12 points. Higher score denotes better function.
Measured: 18 months
Dynamometer
Grip strength
Measured: 6 months
Dynamometer
Grip strength
Measured: 12 months
Dynamometer
Grip strength
Measured: 18 months
6 Minute Walk Test
Endurance. Walking distance during 6 minutes.
Measured: 6 months
6 Minute Walk Test
Endurance. Walking distance during 6 minutes.
Measured: 12 months
6 Minute Walk Test
Endurance. Walking distance during 6 minutes.
Measured: 18 months
ActivPAL
Activity monitoring across seven days
Measured: 6 months
ActivPAL
Activity monitoring across seven days
Measured: 12 months
ActivPAL
Activity monitoring across seven days
Measured: 18 months
Montreal Cognitive Assessment
Cognitive function
Measured: 6 months
Montreal Cognitive Assessment
Cognitive function
Measured: 12 months
Montreal Cognitive Assessment
Cognitive function
Measured: 18 months
Trail making test A and B
Executive function
Measured: 6 months
Trail making test A and B
Executive function
Measured: 12 months
Trail making test A and B
Executive function
Measured: 18 months
Global Deterioration Scale (GDS)
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Measured: 6 months
Global Deterioration Scale (GDS)
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Measured: 12 months
Global Deterioration Scale (GDS)
GDS is a measure of global cognitive function. A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
Measured: 18 months
Hospital Anxiety and Depression Scale (HADS)
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Measured: 6 months
Hospital Anxiety and Depression Scale (HADS)
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Measured: 12 months
Hospital Anxiety and Depression Scale (HADS)
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Measured: 18 months
Fatigue Severity Scale (FSS-7)
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Measured: 6 months
Fatigue Severity Scale (FSS-7)
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Measured: 12 months
Fatigue Severity Scale (FSS-7)
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue. FSS-7 contains seven statements that rate the severity of fatigue. Each item is scored from 1 to 7. Higher score is indicating more fatigue.
Measured: 18 months
Part 2 of the Client Service Receipt Inventory
A measure of caregivers work participation and absenteeism
Measured: 6 months
Part 2 of the Client Service Receipt Inventory
A measure of caregivers work participation and absenteeism
Measured: 12 months
Part 2 of the Client Service Receipt Inventory
A measure of caregivers work participation and absenteeism
Measured: 18 months
Total cholesterol
The level of total cholesterol will be measured by a blood test
Measured: 6 months
Total cholesterol
The level of total cholesterol will be measured by a blood test
Measured: 12 months
Total cholesterol
The level of total cholesterol will be measured by a blood test
Measured: 18 months
Low Density Lipoprotein (LDL)
The LDL level will be measured by a blood test
Measured: 6 months
Low Density Lipoprotein (LDL)
The LDL level will be measured by a blood test
Measured: 12 months
Low Density Lipoprotein (LDL)
The LDL level will be measured by a blood test
Measured: 18 months
High Density Lipoprotein (HDL)
The HDL level will be measured by a blood test
Measured: 6 months
High Density Lipoprotein (HDL)
The HDL level will be measured by a blood test
Measured: 12 months
High Density Lipoprotein (HDL)
The HDL level will be measured by a blood test
Measured: 18 months
Longterm blood sugar (HbA1c)
The HbA1c level will be measured by a blood test
Measured: 6 months
Longterm blood sugar (HbA1c)
The HbA1c level will be measured by a blood test
Measured: 12 months
Longterm blood sugar (HbA1c)
The HbA1c level will be measured by a blood test
Measured: 18 months
Hemoglobin
The hemoglobin level will be measured by a blood test
Measured: 6 months
Hemoglobin
The hemoglobin level will be measured by a blood test
Measured: 12 months
Hemoglobin
The hemoglobin level will be measured by a blood test
Measured: 18 months
Creatinine
The creatinine level will be measured by a blood test
Measured: 6 months
Creatinine
The creatinine level will be measured by a blood test
Measured: 12 months
Creatinine
The creatinine level will be measured by a blood test
Measured: 18 months
C-reactive protein (CRP)
The CRP level will be measured by a blood test
Measured: 6 months
C-reactive protein (CRP)
The CRP level will be measured by a blood test
Measured: 12 months
C-reactive protein (CRP)
The CRP level will be measured by a blood test
Measured: 18 months
Blood pressure
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Measured: 6 months
Blood pressure
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Measured: 12 months
Blood pressure
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
Measured: 18 months
Body mass index (BMI)
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Measured: 6 months
Body mass index (BMI)
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Measured: 12 months
Body mass index (BMI)
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
Measured: 18 months
Health care costs
Data from available registries will be used to estimate costs in Euro
Measured: 18 months
Adherence to the intervention
Number of attended meetings with the stroke coordinator
Measured: 18 months
Exercise Adherence Rating Scale
Exercise Adherence Rating Scale measures the level of adherence to the recommended and agreed activities and the reasons for not adhering.
Measured: 18 months
Patient diaries
Adherence to the recommended and agreed activities
Measured: 18 months
Adverse events
Adverse events will be registered to assess the safety of the intervention.
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Mar 2019
- Study start11 Apr 2019
- Primary completion30 Sep 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by Norwegian University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A two armed parallel group randomized controlled trial
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 301 participants (actual)
Sponsor and investigators
- Lead sponsor
- Norwegian University of Science and Technology
- Sponsor type
- University, hospital or other
- Collaborators
- St. Olavs Hospital, University Hospital, Akershus, Asker & Baerum Hospital, Alesund Hospital
- Responsible party
- Sponsor
- Investigators
- Jorunn Helbostad, phd prof, Study director, Norwegian University for Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03859063
- Sponsor's protocol ID
- 2018/1809
- Acronym
- LAST-long
- Status last verified
- Sep 2025
- First submitted
- 11 Feb 2019
- Last updated
- 16 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ihle-Hansen H, Thommessen B, Langlo SR, Bergh E, Hokstad A, Lydersen S, Seljeseth Y, Saltvedt I, Askim T. Impact of age and frailty on the effect of a multimodal individualized long-term intervention after stroke: the last-long trial. J Rehabil Med. 2026 Oct 26;58:jrm46250. doi: 10.2340/jrm.v58.46250.
PubMed 42929098Askim T, Langlo SR, Bergh E, Dohl O, Ellekjaer H, Hokstad A, Ihle-Hansen H, Indredavik B, Lydersen S, Luzum G, Seljeseth Y, Skandsen T, Saltvedt I, Thommessen B. A multimodal individualized long-term intervention to prevent functional decline after stroke (LAST-long): a single blinded randomised controlled trial. Lancet Reg Health Eur. 2025 Nov 13;61:101531. doi: 10.1016/j.lanepe.2025.101531. eCollection 2026 Feb.
PubMed 41323876Askim T, Hokstad A, Bergh E, Dohl O, Ellekjaer H, Ihle-Hansen H, Indredavik B, Leer ASM, Lydersen S, Saltvedt I, Seljeseth Y, Thommessen B. Multimodal individualised intervention to prevent functional decline after stroke: protocol of a randomised controlled trial on long-term follow-up after stroke (LAST-long). BMJ Open. 2023 May 10;13(5):e069656. doi: 10.1136/bmjopen-2022-069656.
PubMed 37164457Gibson E, Koh CL, Eames S, Bennett S, Scott AM, Hoffmann TC. Occupational therapy for cognitive impairment in stroke patients. Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: 10.1002/14651858.CD006430.pub3.
PubMed 35349186
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multimodal Individualized Intervention to Prevent Functional Decline After Stroke. A Randomized Controlled Trial on Long-term Follow-up After Stroke (The LAST-long Trial)
- ClinicalTrials.gov ID
- NCT03859063
- Acronym / sponsor ID
- LAST-long / 2018/1809
- Conditions
- Stroke
- Keywords
- Rehabilitation, Cognition, Physical Fitness, Case Managers, Secondary prevention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 301 participants (actual)
- Lead sponsor
- Norwegian University of Science and TechnologyUniversity, hospital or other
- Collaborators
- St. Olavs Hospital, University Hospital, Akershus, Asker & Baerum Hospital, Alesund Hospital
- Study start
- 11 Apr 2019 (actual)
- Primary completion
- 30 Sep 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 1 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. These are also regarded as barriers to achieve optimal adherence to the guidelines regarding secondary prevention. The primary aim of this project is to evaluate the effectiveness of a multimodal individualized intervention to prevent functional decline in the long term after stroke.
Detailed description
In a clinical randomized controlled trial, participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months.
The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
Those randomized to the control group will receive standard care.
Patients living in the municipalities of Trondheim, Lørenskog and Skedsmo admitted to Akershus University Hospital or St. Olavs University Hospital will be included at the outpatients clinic 3 months after the stroke.
All patients will be re-assessed at 6, 12 and 18 months after inclusion. Primary outcome will be modified Rankin Scale at 18 months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- A two armed parallel group randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: InterventionRegular follow up by a community based stroke coordinator |
| Control | Active comparator | Behavioral: ControlUsual care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Diagnosis of first ever or recurrent stroke (ischemic stroke or hemorrhage)
- mRS < 5
- Living in Trondheim, Skedsmo or Lørenskog municipality
- Less than 10 points on Short Physical Performance Battery (SPPB) OR less than 26 points on Montreal Cognitive Assessment (MoCA) OR more than 27 points on the 7 item version of the Fatigue Severity Scale (FSS-7) OR more than 7 points on the depression or anxiety items on Hospital Anxiety and Depression Scale (HADS) OR reduced hand function (i.e. fails on Motor Assessment Scale - Advanced arm- and hand function, item 3)
- Able to understand Norwegian
Key exclusion criteria (2 listed)
- Life expectancy < 12 months
- Other serious diseases, judged by the medical doctor to make it difficult to comply with the intervention (i.e. serious neurological diseases or drug abuse).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterventionParticipants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up. | Behavioural | Intervention |
| ControlAlso: Usual careCommunity based follow-up as usual | Behavioural | Control |
Primary outcome
Modified Rankin Scale (mRS)
Time frame: 18 months
mRS is an ordinal scale ranging from 0 to 6 measuring global function. 0 denotes no symptoms while 6 denotes death.
76 secondary outcomes
Modified Rankin Scale (mRS)
Time frame: 6 months
Modified Rankin Scale (mRS)
Time frame: 12 months
Barthel Index
Time frame: 6 months
Barthel Index
Time frame: 12 months
Barthel Index
Time frame: 18 months
Nottingham IADL
Time frame: 6 months
Nottingham IADL
Time frame: 12 months
Nottingham IADL
Time frame: 18 months
Stroke Impact Scale (SIS)
Time frame: 6 months
Stroke Impact Scale (SIS)
Time frame: 12 months
Stroke Impact Scale (SIS)
Time frame: 18 months
The 5-level EQ-5D version (EQ-5D-5L)
Time frame: 6 months
The 5-level EQ-5D version (EQ-5D-5L)
Time frame: 12 months
The 5-level EQ-5D version (EQ-5D-5L)
Time frame: 18 months
Short Physical Performance Battery (SPPB)
Time frame: 6 months
Short Physical Performance Battery (SPPB)
Time frame: 12 months
Short Physical Performance Battery
Time frame: 18 months
Dynamometer
Time frame: 6 months
Dynamometer
Time frame: 12 months
Dynamometer
Time frame: 18 months
6 Minute Walk Test
Time frame: 6 months
6 Minute Walk Test
Time frame: 12 months
6 Minute Walk Test
Time frame: 18 months
ActivPAL
Time frame: 6 months
ActivPAL
Time frame: 12 months
ActivPAL
Time frame: 18 months
Montreal Cognitive Assessment
Time frame: 6 months
Montreal Cognitive Assessment
Time frame: 12 months
Montreal Cognitive Assessment
Time frame: 18 months
Trail making test A and B
Time frame: 6 months
Trail making test A and B
Time frame: 12 months
Trail making test A and B
Time frame: 18 months
Global Deterioration Scale (GDS)
Time frame: 6 months
Global Deterioration Scale (GDS)
Time frame: 12 months
Global Deterioration Scale (GDS)
Time frame: 18 months
Hospital Anxiety and Depression Scale (HADS)
Time frame: 6 months
Hospital Anxiety and Depression Scale (HADS)
Time frame: 12 months
Hospital Anxiety and Depression Scale (HADS)
Time frame: 18 months
Fatigue Severity Scale (FSS-7)
Time frame: 6 months
Fatigue Severity Scale (FSS-7)
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2025.
- Derived from this study: PubMed 42929098Ihle-Hansen H, Thommessen B, Langlo SR, Bergh E, Hokstad A, Lydersen S, Seljeseth Y, Saltvedt I, Askim T. Impact of age and frailty on the effect of a multimodal individualized long-term intervention after stroke: the last-long trial. J Rehabil Med. 2026 Oct 26;58:jrm46250. doi: 10.2340/jrm.v58.46250.
- Derived from this study: PubMed 41323876Askim T, Langlo SR, Bergh E, Dohl O, Ellekjaer H, Hokstad A, Ihle-Hansen H, Indredavik B, Lydersen S, Luzum G, Seljeseth Y, Skandsen T, Saltvedt I, Thommessen B. A multimodal individualized long-term intervention to prevent functional decline after stroke (LAST-long): a single blinded randomised controlled trial. Lancet Reg Health Eur. 2025 Nov 13;61:101531. doi: 10.1016/j.lanepe.2025.101531. eCollection 2026 Feb.
- Derived from this study: PubMed 37164457Askim T, Hokstad A, Bergh E, Dohl O, Ellekjaer H, Ihle-Hansen H, Indredavik B, Leer ASM, Lydersen S, Saltvedt I, Seljeseth Y, Thommessen B. Multimodal individualised intervention to prevent functional decline after stroke: protocol of a randomised controlled trial on long-term follow-up after stroke (LAST-long). BMJ Open. 2023 May 10;13(5):e069656. doi: 10.1136/bmjopen-2022-069656.
- Derived from this study: PubMed 35349186Gibson E, Koh CL, Eames S, Bennett S, Scott AM, Hoffmann TC. Occupational therapy for cognitive impairment in stroke patients. Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: 10.1002/14651858.CD006430.pub3.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jorunn Helbostad, phd prof study director
Norwegian University for Science and Technology
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention in people with Stroke, run by Norwegian University of Science and Technology at 4 sites in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Rankin Scale (mRS) (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03859063, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.